The goal of this clinical trial is to learn if antibiotics (amoxicillin) work to treat chronic low back pain in adults. In some patients, this type of back pain may be caused by bacteria in the vertebrae, resulting in a condition known as "Modic type I change." The main questions the trial aims to answer are: * What is the efficacy (primary objective) of antibiotic treatment for patients with chronic low back pain and Modic type I changes? * What is the cost-effectiveness (secondary objective) of antibiotic treatment for patients with chronic low back pain and Modic type I changes? Researchers will compare amoxicillin to a placebo (a look-alike substance that contains no active drug) to see if amoxicillin works to treat chronic low back pain. Participants in the trial will: * Be invited for an MRI scan to determine if they have a Modic type I change; those who do will be included in the study. * Take either amoxicillin or a placebo daily for 100 days. * Take probiotics daily for 100 days to reduce the occurrence and impact of any side effects from the antibiotics. * Attend clinic visits at baseline (the start), 4 weeks, 3 months, and 12 months for checkups and tests. * Complete questionnaires at baseline, 3 months, 6 months, and 12 months.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
204
Antibiotic treatment (amoxicillin) with a dosage of 1000 mg (3 times a day) for a period of 100 days
Placebo with a dose of 1000 mg (3 times a day) for a period of 100 days
Erasmus Medical Center
Rotterdam, South Holland, Netherlands
RECRUITINGRoland Morris Disability Questionnaire (RMDQ)
The primary outcome is pain and disability measured with the Roland Morris Disability Questionnaire (RMDQ). The scale ranges from 0-24 in which a higher score indicates higher disability. The RMDQ was also the primary outcome in the previous trials, and it is a recommended core outcome measure for trials in LBP.
Time frame: The measurements are scheduled at baseline and at 3, 6 and 12 months follow-up.
LBP-intensity (0-10 NRS-scale)
In the form of a questionnaire
Time frame: Measured at baseline, 3 months, 6 months and 12 months
Leg pain intensity (0-10 NRS-scale)
In the form of a questionnaire
Time frame: Measured at baseline, 3 months, 6 months and 12 months
Health-related quality of life (PROMIS-GH-10)
In the form of a questionnaire
Time frame: Measured at baseline, 3 months, 6 months and 12 months
Health-related quality of life (EQ-5D-5L)
In the form of a questionnaire
Time frame: Measured at baseline, 3 months, 6 months and 12 months
Self-reported number of days with sick leave
In the form of a questionnaire
Time frame: Measured at baseline, 3 months, 6 months and 12 months
Co-interventions (pharmacological and non-pharmacological)
In the form of a questionnaire
Time frame: Measured at baseline, 3 months and 12 months
Global perceived effect (7-point Likert scale)
In the form of a questionnaire
Time frame: Measured at 3 months, 6 months and 12 months
Patients' satisfaction with treatment (7-point Likert scale)
In the form of a questionnaire
Time frame: Measured at baseline, 3 months and 12 months
Success of blinding
In the form of a questionnaire
Time frame: Measured at 3 months and 12 months
Compliance
A pill count will be conducted
Time frame: Measured at 3 months
Pain self-efficacy (Pain Self-Efficacy Questionnaire)
In the form of a questionnaire
Time frame: Measured at baseline, 3 months, 6 months and 12 months
Sleep questionnaire (Pittsburgh Sleep Quality Index)
In the form of a questionnaire
Time frame: Measured at baseline, 3 months, 6 months and 12 months
Neuropathic pain (PainDETECT)
In the form of a questionnaire
Time frame: Measured at baseline, 3 months, 6 months and 12 months
Cost questionnaires (Medical Consumption Questionnaire)
In the form of a questionnaire
Time frame: Measured at 3 months, 6 months and 12 months
Cost questionnaires (Productivity Cost Questionnaire)
In the form of a questionnaire
Time frame: Measured at 3 months, 6 months and 12 months
Gut microbiome composition
The possible collateral impact of antibiotics on the microbiome would be investigated by comparing the abundance and diversity of microbial and resistome composition between patients in amoxicillin and placebo groups. They would be characterized using whole shotgun and functional metagenomic sequencing data (Dhariwal et al. Gut Microbes, 2023). In short, stools of the patients will be collected at baseline, 3 months, and 12 months. From these samples, the microbial DNA will be extracted using a commercial kit. Libraries for shotgun metagenomic sequencing would be prepared using Ilumina sequencing platform. Low quality and adapter sequences from paired-end reads will be filtered, and human DNA contaminant sequences will be discarded. The high-quality reads will be subjected to taxonomic classification. CARD antimicrobial resistance database will be used to annotate metagenomic reads.
Time frame: Measured at baseline, 3 months, and 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.